New treatments in acute ischemic stroke

Area of Science:

• Neurology
• Cardiovascular Medicine
• Pharmacology

Background:

• The management of acute ischemic stroke has evolved with the introduction of intravenous thrombolysis.
• Current focus includes immediate clot lysis, with institutions becoming certified stroke centers to facilitate rapid treatment.
• Despite advancements, acute treatment options beyond aspirin and intravenous tPA are limited.

Purpose of the Study:

• To review the current landscape of acute ischemic stroke treatment.
• To discuss the limitations of existing therapies and the ongoing development of new treatment strategies.
• To highlight the pursuit of neuroprotective agents as a critical area of research.

Main Methods:

• Review of current therapeutic options for acute ischemic stroke.
• Discussion of US Food and Drug Administration-approved treatments.
• Exploration of investigational therapies including intra-arterial thrombolysis and neuroprotectants.

Main Results:

• Intravenous recombinant tissue plasminogen activator (tPA) is the primary FDA-approved agent for acute ischemic stroke.
• Evidence supporting routine use of heparin or low-molecular-weight heparinoids is lacking.
• Advanced treatments like intra-arterial thrombolysis are restricted to specialized stroke centers.
• Neuroprotectant strategies have not yet proven successful in clinical trials.

Conclusions:

• Acute ischemic stroke management has shifted towards rapid thrombolysis.
• Treatment options remain limited, necessitating further research into novel lytic agents and antithrombotics.
• The development of effective neuroprotective drugs is a critical, yet unmet, goal in acute stroke therapy.